COVID-19 vaccine

Icosavax Launches COVID-19 Vaccine Program with Preclinical Data and $16.5 Million in New Funding

Friday, October 30, 2020 - 9:34pm

In addition, Icosavax received $6.5 million from Open Philanthropy to support development of the companys vaccine platform technology and COVID-19 vaccine candidate.

Key Points: 
  • In addition, Icosavax received $6.5 million from Open Philanthropy to support development of the companys vaccine platform technology and COVID-19 vaccine candidate.
  • To enable rapid progress of the companys COVID-19 vaccine candidate to the clinic, Amgen has agreed to manufacture a key intermediate for initial clinical studies.
  • The team at Icosavax is dedicated to advancing vaccines against severe life-threatening respiratory diseases to protect our most at-risk populations.
  • In addition to the COVID-19 vaccine candidate, Icosavax is also advancing IVX-121 into clinical trials as a potential vaccine for respiratory syncytial virus (RSV) for older adults.

Generex Subsidiary NuGenerex Immuno-Oncology Announces Appointment of Dr. Tamera Coyne-Beasley to the Scientific Advisory Board for its COVID-19 Vaccine Development Program

Friday, October 30, 2020 - 1:00pm

Generex CEO, Joseph Moscato said, We are honored that Dr. Coyne-Beasley has joined our scientific and clinical advisory board.

Key Points: 
  • Generex CEO, Joseph Moscato said, We are honored that Dr. Coyne-Beasley has joined our scientific and clinical advisory board.
  • The company has also turned its Ii-Key technology on infectious disease, responding to the coronavirus pandemic with a SARS-CoV-2 vaccine development program.
  • Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
  • Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Joint press release: EU-Canada Leaders' virtual meeting

Friday, October 30, 2020 - 8:03am

The President of the European Council, Charles Michel, the President of the European Commission, Ursula von der Leyen, and the Prime Minister of Canada, Justin Trudeau, held a Leaders' Virtual Meeting on 29 October 2020.

Key Points: 
  • The President of the European Council, Charles Michel, the President of the European Commission, Ursula von der Leyen, and the Prime Minister of Canada, Justin Trudeau, held a Leaders' Virtual Meeting on 29 October 2020.
  • They shared the commitment to take effective measures to protect health, ensure a robust economic recovery, and build more innovative, sustainable, inclusive and resilient economies.
  • In this way the EU and Canada will emerge from this crisis stronger than before and in a better position to addresschallenges of the future.
  • Since the start of the pandemic, the EU and Canada have been cooperating closely, including to ensure universal, equitable and affordable access to COVID-19 vaccines, treatments and tests.
  • The leaders agreed that the EU and Canada will deepen their cooperation and exchange of information on COVID-19 vaccines including research, access, procurement and distribution.
  • Both sides will continue to provide joint leadership in strengthening the WHO, and the global pandemic preparedness and response capacity more generally.
  • They agreed to deepen their work towards a strategic partnership on critical raw materials to support the green and digital transition.
  • On China, the EU and Canada expressed their deep concern about the continued arbitrary detention there of Canadians, EU and other foreign nationals.
  • The leaders acknowledged the role of strong transatlantic relations in helping to better address current geopolitical challenges.

UCLA Begins Recruitment For Phase 3 Of The Oxford University - AstraZeneca COVID-19 Vaccine Trial

Thursday, October 29, 2020 - 7:01pm

The vaccine, developed by Oxford University and AstraZeneca, is called AZD1222and has successfully gone through earlier smaller phase 1 and 2 trials.

Key Points: 
  • The vaccine, developed by Oxford University and AstraZeneca, is called AZD1222and has successfully gone through earlier smaller phase 1 and 2 trials.
  • The phase 3 trial is designed to determine whether two doses of the vaccine can prevent symptomatic COVID-19.
  • Recruitment for the trial has resumed following a brief pause after the FDA, the independent Data and Safety Monitoring Board, and AstraZeneca reviewed a possible adverse reaction seen in a trial participant in the United Kingdom.
  • UCLA is part of the COVID-19 Prevention Network (CoVPN) participating in the phase 3 trial.

Joint press release: EU-Canada Leaders' Virtual Meeting

Thursday, October 29, 2020 - 3:35pm

The leaders agreed that the EU-and Canada will deepen their cooperation and exchange of information on COVID-19 vaccines including research, access, procurement and distribution.

Key Points: 
  • The leaders agreed that the EU-and Canada will deepen their cooperation and exchange of information on COVID-19 vaccines including research, access, procurement and distribution.
  • Both sides will continue to provide joint leadership in strengthening the WHO, and the global pandemic preparedness and response capacity more generally.
  • They agreed to deepen their work towards a strategic partnership on critical raw materials to support the green and digital transition.
  • The leaders acknowledged the role of strong transatlantic relations in helping to better address current geopolitical challenges.

Stirling Ultracold Helps Communities Around the World Prepare to Administer COVID-19 Vaccination

Thursday, October 29, 2020 - 1:13pm

Stirling Ultracold recognizes just how devastating this magnitude of loss would be for a COVID-19 vaccine.

Key Points: 
  • Stirling Ultracold recognizes just how devastating this magnitude of loss would be for a COVID-19 vaccine.
  • Promising vaccine contenders, like Pfizer and Moderna, have already reported storage temperature requirements ranging from -20C to -80C (-4F to -112F).
  • International leaders tasked with COVID-19 preparedness responsibilities have also contacted Stirling Ultracold for immediate partnership with their portable ULT freezer solution.
  • We're grateful to have a trusted partner like Stirling Ultracold to help clinics and healthcare locations prepare for one of the largest vaccinations in history and serve their communities as effectively as possible."

Emulate Signs Collaborative Agreement with the FDA to Apply Lung-Chip to Evaluate Safety of COVID-19 Vaccines and Protective Immunity Against SARS-CoV-2

Thursday, October 29, 2020 - 11:00am

Under the CRADA, the FDA will use a range of Organ-Chips from Emulate to study the safety, efficacy, and mechanisms of drugs regulated by the FDA.

Key Points: 
  • Under the CRADA, the FDA will use a range of Organ-Chips from Emulate to study the safety, efficacy, and mechanisms of drugs regulated by the FDA.
  • This new CRADA agreement follows the successful completion of the first Emulate CRADA with the FDA initiated in 2017 that focused on toxicity studies using the Liver-Chip.
  • Knowledge obtained from the study will provide insights into antibody dependent enhancement (ADE), which is relevant to evaluating the safety of vaccines for COVID-19.
  • The CRADA is led by the FDAs Office of the Chief Scientist, allowing for studies across FDA offices with Organ-Chips from Emulate.

Takeda Expands COVID-19 Vaccine Supply in Japan Through Partnership with Moderna and Government of Japan

Thursday, October 29, 2020 - 6:00am

This effort is part of a three-way agreement among Takeda, Moderna and the Government of Japans Ministry of Health Labour and Welfare (MHLW).

Key Points: 
  • This effort is part of a three-way agreement among Takeda, Moderna and the Government of Japans Ministry of Health Labour and Welfare (MHLW).
  • Takeda is collaborating with the Japanese Government and vaccine developers to provide rapid and sustained access to COVID-19 vaccines in Japan, said Rajeev Venkayya, M.D., President of the Global Vaccine Business Unit, Takeda.
  • Moderna will provide finished product and will support Takeda with its development and regulatory efforts.
  • Takeda has partnered with the Government of Japan, Novavax and Moderna, to help accelerate the availability of a COVID-19 vaccine.

Skoll Foundation Funds Sabin Vaccine Institute, Dalberg and JSI Research & Training Institute, Inc. to Establish COVID-19 Vaccine Equity Project

Wednesday, October 28, 2020 - 3:00pm

WASHINGTON, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) today announced that it has partnered with Dalberg and JSI Research & Training Institute, Inc. (JSI) to create the COVID-19 Vaccine Equity Project (vaccineequity.org).

Key Points: 
  • WASHINGTON, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute (Sabin) today announced that it has partnered with Dalberg and JSI Research & Training Institute, Inc. (JSI) to create the COVID-19 Vaccine Equity Project (vaccineequity.org).
  • The Skoll Foundation is supporting the creation of the COVID-19 Vaccine Equity Project through start-up funding of $1 million to pilot the program in four countries.
  • This project leverages the three partners global reach and decades of experience in immunization systems strengthening to facilitate national planning.
  • The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation.

Russian application of Sputnik V vaccine for WHO vaccine prequalification among the first applications submitted

Tuesday, October 27, 2020 - 5:13pm

The Russian Federation has become one of the first countries to apply to WHO for prequalification of its vaccine against the novel coronavirus infection.

Key Points: 
  • The Russian Federation has become one of the first countries to apply to WHO for prequalification of its vaccine against the novel coronavirus infection.
  • The Prequalification of Medicines Programme is a United Nations programme managed by WHO.
  • Successful prequalification will enable Sputnik V to be included in the list of medicines used by international procurement agencies and countries to guide bulk purchasing of medicines.
  • We have submitted an application for Emergency Use Listing and prequalification of the vaccine by the World Health Organization, which will allow Sputnik V to be included in the list of medical products that meet leading quality, safety and efficacy standards.